Tumor necrosis factor inhibitors in psoriatic arthritis.

about

Umbilical cord blood stem cell treatment for a patient with psoriatic arthritis.

P2860

Q47409766-A2F9FFAB-2736-4A35-9F60-94919EE74099

P2860

Tumor necrosis factor inhibitors in psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q38685543

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Tumor necrosis factor inhibitors in psoriatic arthritis.

@en

type

Item

label

Tumor necrosis factor inhibitors in psoriatic arthritis.

@en

prefLabel

Tumor necrosis factor inhibitors in psoriatic arthritis.

@en

P1476

Tumor necrosis factor inhibitors in psoriatic arthritis

@en

P2093

Alexis Ogdie

http://www.w3.org/2001/XMLSchema#string

Santhi Mantravadi

http://www.w3.org/2001/XMLSchema#string

Walter K Kraft

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

An endotoxin-induced serum factor that causes necrosis of tumors

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?

Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

Psoriatic Arthritis.

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

P304

899-910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17512433.2017.1329009

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28490202

http://www.w3.org/2001/XMLSchema#string

P932

6348387

http://www.w3.org/2001/XMLSchema#string

Tumor necrosis factor inhibitors in psoriatic arthritis.

about

P2860

P2860

Tumor necrosis factor inhibitors in psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932